Miniatura

Fitxers

701544.pdf (3.35 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-05-06

Llicència de publicació

cc-by (c) Mothe, Beatriz et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/174259

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fimmu.2020.00823

Resum

Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulted in increased histone acetylation, cell-associated HIV-1 RNA, and T-cell activation, which were associated with a marginally significant reduction of the viral reservoir. Vaccinations boosted robust and broad HIVconsv-specific T cells, which were strongly refocused toward conserved regions of the HIV-1 proteome. During a monitored ART interruption phase using plasma viral load over 2,000 copies/ml as a criterium for ART resumption, 23% of individuals showed sustained suppression of viremia up to 32 weeks without evidence for reseeding the viral reservoir. Results from this pilot study show that the combined kick&kill intervention was safe and suggest a role for this strategy in achieving an immune-driven durable viremic control.

Matèries

VIH (Virus), Vacunació

Matèries (anglès)

HIV (Viruses), Vaccination

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

MOTHE, Beatriz, ROSAS-UMBERT, Miriam, COLL, Pep, MANZARDO, Christian, PUERTAS CASTRO, Ma. carmen, MORÓN-LÓPEZ, Sara, LLANO, Anuska, MIRANDA, Cristina, CEDEÑO, Samandhy, LÓPEZ, Miriam, ALARCÓN-SOTO, Yovaninna, GÓMEZ MELIS, Guadalupe, LANGOHR, Klaus, BARRIOCANAL, Ana m., TORO, Jessica, RUIZ, Irene, ROVIRA, Cristina, CARRILLO, Antonio, MEULBROEK, Michael, CROOK, Alison, WEE, Edmund g., MIRÓ MEDA, José m. (josé maría), CLOTET, Bonaventura, VALLE, Marta, MARTÍNEZ PICADO, Francisco javier, HANKE, Tomás, BRANDER, Christian, MOLTÓ, José, B.C.N02 Study Investigators. HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). _Frontiers in Immunology_. 2020. Vol. 11, núm. 823. [consulta: 15 de gener de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/174259]

Exportar metadades

JSON - METS

Compartir registre